Adenosine 2A receptor agonism: A single intrathecal administration attenuates motor paralysis in experimental autoimmune encephalopathy in rats

Lisa C Loram, Keith A Strand, Frederick R Taylor, Evan Sloane, Anne-Marie Van Dam, Jayson Rieger, Steven F Maier, Linda R Watkins

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

A single intrathecal dose of adenosine 2A receptor (A2AR) agonist was previously reported to produce a multi-week reversal of allodynia in two different models of neuropathic pain in addition to downregulating glial activation markers in the spinal cord. We aimed to determine whether a single intrathecal administration of an A2AR agonist was able to attenuate motor symptoms induced by experimental autoimmune encephalopathy. Two A2AR agonists (CGS21680 and ATL313) significantly attenuated progression of motor symptoms following a single intrathecal administration at the onset of motor symptoms. OX-42, a marker of microglial activation, was significantly attenuated in the lumbar spinal cord following A2AR administration compared to vehicle. Therefore, A2AR agonists attenuate motor symptoms of EAE by acting on A2AR in the spinal cord.

Original languageEnglish
Pages (from-to)50-54
Number of pages5
JournalBrain Behavior and Immunity
Volume46
DOIs
Publication statusPublished - May 2015

Cite this